Synthon Announces Successful Outcomes from Phase III Study of Synthon’s Glatiramer Acetate

04-May-2015 - Synthon announces that data from the open-label extension of the Phase III GATE study of the Company’s generic glatiramer acetate in patients with relapsing remitting multiple sclerosis (RRMS) demonstrate that efficacy, safety and tolerability were maintained over the entire two-year study ...

Antitope and Synthon announce collaboration

04-Jul-2014 - Antitope Limited, an Abzena company, announced that it will collaborate with Synthon Biopharmaceuticals BV, to assess the potential immunogenicity of candidate antibodies for Synthon’s ADC programmes.Antitope will use its EpiScreen™ technology, a highly accurate and sensitive ex vivo human T ...

Synthon and MAB Discovery sign discovery agreement

09-May-2014 - Synthon Biopharmaceuticals BV and MAB Discovery GmbH announced the execution of a research and license agreement. Under the terms of the agreement, MAB Discovery will generate antibodies for targets selected by Synthon in support of the company’s development of antibody-drug conjugates (ADCs) and ...

Bioceros awarded GO EFRO grant in consortium led by Synthon

27-Sep-2012 - Bioceros BV announced that it participates in the ACCESS project consortium led by Synthon, which has been awarded a grant within the GO EFRO program. The budget of almost €1 million is available for the development of improved antibody manufacturing systems. Other partners in this consortium are ...

Synthon enters into global license agreement with Amgen and Watson for biosimilar trastuzumab

20-Jul-2012 - Synthon announced that it has entered into a global license agreement with Amgen Inc. and Watson Pharmaceuticals, Inc. for Synthon’s trastuzumab, being developed as a biosimilar to Herceptin®, which is currently approved for treatment of breast cancer and gastric cancer. Earlier this year Synthon ...

Synthon sued for infringing certain patents for Copaxone

Synthon intends to defend vigorously

10-Apr-2012 - Synthon has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for glatiramer acetate, 20 mg/ml solution for injection in pre-filled syringes. The reference listed drug for glatiramer acetate is Copaxone, indicated for reduction of the frequency of ...

Synthon Successfully Concluded Phase I Clinical Trial for Trastuzumab

Synthon’s first truly biosimilar product now embarking on phase III study

26-Mar-2012 - Synthon announced that it has successfully concluded a phase I clinical trial for trastuzumab, a biosimilar to Herceptin©, for treatment of breast cancer and gastric cancer. The company will now initiate a phase III clinical trial for trastuzumab, bringing an affordable alternative for treatment ...

Synthon receives European approvals for Rosuvastatin

23-Jan-2012 - Synthon announced today that it has successfully concluded multiple registration procedures for Rosuvastatin 5mg, 10mg, 15mg, 20mg and 40mg film-coated immediate release tablets. Regulatory clearance for Rosuvastatin has been obtained in 14 European countries.

Synthon announces European approvals for Eplerenone

19-Sep-2011 - Synthon announced that it has successfully concluded multiple registration procedures for the cardiovascular drug Eplerenone. Synthon has obtained regulatory clearance for the product in nine European countries, for both 25 and 50 mg film coated tablets.Synthon's Eplerenone is a fully generic and ...

Synthon acquires Syntarga and its Antibody-Drug Conjugate Technology

28-Jun-2011 - Synthon announced its acquisition of Syntarga BV. Syntarga’s activities are focused on the development of innovative chemistries that arm antibodies with a cytotoxic payload - yielding successful Antibody-Drug Conjugate (ADC) products that specifically target and kill cancer cells.“Through this ...